Findings from two randomized trials provide further evidence to suggest that hydroxychloroquine has no benefits for the prevention or treatment of COVID-19.
Patients with psoriatic arthritis undergoing stable treatment with tofacitinib plus methotrexate may be able to withdraw methotrexate without having an adverse impact on disease activity, suggests a substudy of the OPAL Balance trial.
Use of hydroxychloroquine for the treatment of rheumatic and musculoskeletal diseases is not associated with a reduction in COVID-19 mortality risk, suggest findings from an observational study published in The Lancet Rheumatology.
An 8-week intensive course of electro-acupuncture could improve pain and function in patients with knee osteoarthritis, with the effects lasting for up to 26 weeks, Chinese research shows.
Treatment with oral prednisolone on a step-down regimen may reduce disease activity in people with axial spondyloarthritis but has minimal impact on other outcomes such as functional improvement, Indian researchers report.
A meta-analysis of randomized controlled trials has found no significant association between Janus kinase inhibitor use and the risk for venous thromboembolism among patients with immune-mediated inflammatory diseases.
Findings from the second part of the LILAC trial suggest that BIIB059, a monoclonal antibody targeting blood dendritic cell antigen 2, improves skin outcomes for patients with active cutaneous lupus erythematosus.
“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.
Deucravacitinib, a novel selective tyrosine kinase 2 inhibitor, may be a promising treatment option for patients with psoriatic arthritis, suggest phase 2 data presented in a poster at the ACR Convergence 2020 virtual meeting.
A survey of Veterans Affairs rheumatology consortium members has given greater insight into the experiences and opinions of rheumatology providers during the COVID-19 pandemic.
The autotaxin inhibitor ziritaxestat may improve skin fibrosis in patients with early diffuse cutaneous systemic sclerosis, show data from the phase 2a NOVESA study presented at the ACR Convergence 2020 virtual meeting.
Evobrutinib does not improve treatment response in patients with rheumatoid arthritis who do not respond adequately to methotrexate, phase IIb study data indicate.
The JAK inhibitor tofacitinib is a promising treatment option for people with ankylosing spondylitis, suggest phase 3 trial findings presented at the ACR Convergence 2020 virtual meeting.
Mavrilimumab is effective for reducing the risk for flare and maintaining sustained remission in patients with giant cell arteritis, phase 2 study findings show.
Among patients with gout, those who receive febuxostat treatment do not have a higher risk for cardiovascular events than those on allopurinol, according to the results of the FAST trial.
COVID-19 is uncommon in children with rheumatic diseases and appears to result in mild illness when it occurs, suggest data presented at the ACR Convergence 2020 virtual meeting.
Research presented at the ACR Convergence 2020 virtual meeting provides reassurance that pregnant women with rheumatic diseases can expect a favorable outcome if they develop COVID-19.
Patients with rheumatic diseases taking biologic therapy were more likely to shield during the first 6 months of the COVID-19 pandemic than those taking other drug types, shows research reported at the ACR Convergence 2020 virtual meeting.
Patients with rheumatoid arthritis from the USA made substantial changes to their medication use during the first few months of the COVID-19 pandemic, research shows.